Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy.
Benzaquén A, Giménez E, Iacoboni G, Guerreiro M, Hernani R, Albert E, Carpio C, Balaguer A, Pérez A, S de la Asunción C, Sánchez-Salinas MA, Chorão P, Piñana JL, Beas F, Montoro J, Hernández-Boluda JC, Facal A, Ferrer B, Villalba M, Amat P, Goméz MD, Campos D, Terol MJ, Sanz J, Barba P, Navarro D, Solano C. Benzaquén A, et al. Among authors: carpio c. Bone Marrow Transplant. 2024 Jan;59(1):93-100. doi: 10.1038/s41409-023-02114-0. Epub 2023 Nov 2. Bone Marrow Transplant. 2024. PMID: 37919456
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.
Hodkinson BP, Schaffer M, Brody JD, Jurczak W, Carpio C, Ben-Yehuda D, Avivi I, Forslund A, Özcan M, Alvarez J, Ceulemans R, Fourneau N, Younes A, Balasubramanian S. Hodkinson BP, et al. Among authors: carpio c. Transl Oncol. 2021 Jan;14(1):100977. doi: 10.1016/j.tranon.2020.100977. Epub 2020 Dec 6. Transl Oncol. 2021. PMID: 33395752 Free PMC article.
Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
Carpio C, Iacoboni G, Villacampa G, Catalá E, Bobillo S, Pérez A, Jiménez M, Segura L, Olivé M, Farriols A, Abrisqueta P, Valcárcel D, Carreras MJ, Bosch F, Barba P. Carpio C, et al. Leuk Lymphoma. 2021 Sep;62(9):2288-2291. doi: 10.1080/10428194.2021.1913141. Epub 2021 Apr 24. Leuk Lymphoma. 2021. PMID: 33899648 No abstract available.
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M. Rejeski K, et al. Among authors: carpio c. J Immunother Cancer. 2022 May;10(5):e004475. doi: 10.1136/jitc-2021-004475. J Immunother Cancer. 2022. PMID: 35580927 Free PMC article.
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Domínguez MLG, Pina JMS, Mussetti A, Sancho JM, Bastos-Oreiro M, Catala E, Delgado J, Henriquez HL, Sanz J, Calbacho M, Bailén R, Carpio C, Ribera JM, Sureda A, Briones J, Hernandez-Boluda JC, Cebrián NM, Martin JLD, Martín A, Barba P. Kwon M, et al. Among authors: carpio c. Haematologica. 2023 Jan 1;108(1):110-121. doi: 10.3324/haematol.2022.280805. Haematologica. 2023. PMID: 35770532 Free PMC article.
Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy.
Márquez-Algaba E, Iacoboni G, Pernas B, Esperalba J, Los Arcos I, Navarro V, Monforte A, Beas F, Albasanz-Puig A, Carpio C, Barba P, Ruiz-Camps I. Márquez-Algaba E, et al. Among authors: carpio c. Transplant Cell Ther. 2022 Dec;28(12):851.e1-851.e8. doi: 10.1016/j.jtct.2022.09.007. Epub 2022 Sep 20. Transplant Cell Ther. 2022. PMID: 36221995 Free article.
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G, Navarro V, Martín-López AÁ, Rejeski K, Kwon M, Jalowiec KA, Amat P, Reguera-Ortega JL, Gallur L, Blumenberg V, Gutiérrez-Herrero S, Roddie C, Benzaquén A, Delgado-Serrano J, Sánchez-Salinas MA, Bailén R, Carpio C, López-Corral L, Hernani R, Bastos M, O'Reilly M, Martín-Martín L, Subklewe M, Barba P. Iacoboni G, et al. Among authors: carpio c. J Clin Oncol. 2024 Jan 10;42(2):205-217. doi: 10.1200/JCO.23.01097. Epub 2023 Oct 24. J Clin Oncol. 2024. PMID: 37874957
145 results